Publications by authors named "Michele Gaca"

Background: The safety and efficacy of sodium-glucose cotransporter 2 (SGLT2) inhibitors in hospitalized patients are unclear.

Purpose: To evaluate outcomes of inpatient SGLT2 inhibitor use.

Data Sources: MEDLINE, Embase, Emcare, and Cochrane databases were searched through 29 May 2024.

View Article and Find Full Text PDF

Aim: Incorporating health-related quality of life (HRQoL) measures into health economic analyses can help to provide evidence to inform decisions about how to improve patient outcomes in the most cost-effective manner. The aim of this narrative review was to assess which HRQoL instruments have been used in economic evaluations of type 2 diabetes management including in Indigenous communities.

Method: MEDLINE (Ovid), Embase (Ovid) and Cochrane were searched from inception to June 2022.

View Article and Find Full Text PDF
Article Synopsis
  • * A systematic review of 11 studies found that multianalyte sensors, which can measure glucose and other key substances, show promise for improving diabetes management, but the existing literature is limited.
  • * The review suggests that while current sensor technology can accurately measure various analytes, further human studies are essential to confirm their effectiveness in diabetes self-management and to drive technological advancements.
View Article and Find Full Text PDF

Background: Natural language processing (NLP) may help evaluate the characteristics, prevalence, trajectory, treatment, and outcomes of behavioural disturbance phenotypes in critically ill patients.

Methods: We obtained electronic clinical notes, demographic information, outcomes, and treatment data from three medical-surgical ICUs. Using NLP, we screened for behavioural disturbance phenotypes based on words suggestive of an agitated state, a non-agitated state, or a combination of both.

View Article and Find Full Text PDF

Continuous glucose monitoring (CGM) is rapidly becoming a vital tool in the management of type 1 diabetes. Its use has been shown to improve glycaemic management and reduce the risk of hypoglycaemic events. The cost of CGM remains a barrier to its widespread application.

View Article and Find Full Text PDF